

Edgar Filing: CEL SCI CORP - Form 8-K

CEL SCI CORP
Form 8-K
December 12, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 7, 2017

CEL-SCI CORPORATION

(Exact name of Registrant as specified in its charter)

Colorado	01-11889	84-0916344
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A

(Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (ss.203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (ss.204.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Edgar Filing: CEL SCI CORP - Form 8-K

Exchange Act. []

1

Item 8.01 Other Events

On December 7, 2017, the Company issued a press release, filed as Exhibit 99.1, concerning the observations and recommendations the Independent Data Monitoring Committee (IDMC) for the Company's Phase 3 head and neck cancer study of Multikine.

The IDMC:

- a) saw no evidence of any significant safety questions, and
- b) recommended that the Company continue the study.

On December 11, 2017, the Company issued a press release, filed as Exhibit 99.2, announcing that no further enrollment was required for the Company's Phase 3 head and neck cancer study of Multikine.

Item 9.01 Exhibits

Exhibit Number	Description of Document
-----	-----
99.1	December 7, 2017 press release
99.2	December 11, 2017 press release

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 12, 2017

CEL-SCI CORPORATION

By: /s/ Patricia B. Prichep

 Patricia B. Prichep
 Senior Vice President of Operations